Twenty-one patients with esophageal cancer who received pre-treatment <sup>18</sup>F-FDG PET/CT (PET1) and inter-fractional <sup>18</sup>F-FDG PET/CT (PET2) after 11 fractions of RT (median 23.1 Gy, 2.1 Gy per fraction) were retrospectively reviewed.
18F-FAMT PET Is Useful to Distinguish between Specific Uptake and Nonspecific Uptake Compared to 18F-Flourodeoxyglucose Position Emission Tomography in Esophageal Cancer Patients.